Berman Tabacco Announces Investigation of Applied Therapeutics, Inc. (APLT) for Potential Securities Law ViolationsNewsfile Corp • 01/04/22
Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic DisorderBenzinga • 01/03/22
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD DeficiencyGlobeNewsWire • 12/16/21
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of MetabolismGlobeNewsWire • 11/18/21
Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia KidsGlobeNewsWire • 10/18/21
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes AssociationGlobeNewsWire • 06/25/21
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes AssociationGlobeNewsWire • 06/21/21
Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic DisorderBenzinga • 06/17/21
Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for GalactosemiaGlobeNewsWire • 06/17/21
Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare ConferenceGlobeNewsWire • 06/01/21
Applied Therapeutics to Present at the UBS Global Healthcare Virtual ConferenceGlobeNewsWire • 05/19/21
Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial ResultsGlobeNewsWire • 03/18/21
Applied Therapeutics to Present at the Cowen and Barclays Investor ConferencesGlobeNewsWire • 02/23/21
Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common StockGlobeNewsWire • 02/11/21